HK Stock Market Move | XUANZHUBIO-B(02575) rose over 12% in early trading, with a year-on-year increase in gross profit of 102.33% in 25 years. The commercial layout of Anjiuwei has expanded.

XUANZHUBIO-B(02575) rose more than 12% in early trading, up 12.24% as of press time, at 34 Hong Kong dollars, with a turnover of 6.5058 million Hong Kong dollars. On the news front, recently, XUANZHUBIO-B released its annual performance for the year ending December 31, 2025. The group achieved revenue of 51.772 million yuan, an increase of 72.03% year-on-year; gross profit of 33.369 million yuan, an increase of 102.33% year-on-year; a net loss attributable to the parent company of 246 million yuan, a decrease of 55.88% year-on-year; with a loss per share of 0.53 yuan. During the reporting period, the group adopted flexible and targeted business strategies to maximize the advantages of each listed product and target market, achieving remarkable results. By the end of the reporting period, in the commercialization layout of the digestive system disease drug Anjiuwei, the group used a distribution model combining provincial agents and refined investment promotion, formed an internal sales team of 48 people, and built a sales network covering over 90 distributors and radiating to more than 2,000 medical institutions nationwide; in the commercial promotion of the oncology drugs Xuanyuning and Xuanfeining, the group implemented a direct sales strategy driven by both market and medical factors, formed a professional business team of over 150 people, and orderly promoted the commercialization process of listed products in the domestic market.